Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA network open"
DOI: 10.1001/jamanetworkopen.2022.20957
Abstract: Importance The effectiveness of monoclonal antibodies (mAbs), casirivimab-imdevimab and sotrovimab, is unknown in patients with mild to moderate COVID-19 caused by the SARS-CoV-2 Delta variant. Objective To evaluate the effectiveness of mAb against the Delta… read more here.
Keywords: casirivimab imdevimab; imdevimab; effectiveness; mab treatment ... See more keywords
Disparities in Monoclonal Antibody (mAb) Treatment Usage in the Military Health System During the COVID-19 Pandemic
Sign Up to like & getrecommendations! Published in 2025 at "Journal of General Internal Medicine"
DOI: 10.1007/s11606-025-09715-z
Abstract: Monoclonal antibodies (mAbs) were identified in 2020 as potential curative agents for COVID-19, particularly in high-risk populations. However, studies report differences in receipt of mAbs by race, sex, and insurance status. We hypothesized that Military… read more here.
Keywords: high risk; treatment; military health; mab treatment ... See more keywords